PEG-MGF goes to an FDA panel with no human data. Products sold as "MGF" have held three different molecules.

Why this note exists

PEG-MGF is the last of the five substances on FDA's announced compounding agenda that pepmg had not yet audited. FDA's early announcement, current as of April 15, 2026, lists cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II and "Mechano Growth Factor, Pegylated (PEG-MGF)" for a Pharmacy Compounding Advisory Committee meeting "before the end of February 2027," and says the time and location "will be scheduled in the coming months."[1] As of October 10, 2026, that page gives no date and no briefing document.

The name hides a problem. Mechano growth factor has been used for a gene transcript, for a short synthetic peptide, for a longer protein and, in the PEG-MGF case, for a commercially pegylated version of something. This note sets out the regulatory record, what the human literature actually measured, what happened when other laboratories tested the core claim, and what doping laboratories found when they analyzed products sold under the name.

The regulatory record

Not approved, scheduled for discussion, and on FDA's safety-risk page

An openFDA query of Drugs@FDA data on October 10, 2026 returned no application with mechano growth factor, MGF or PEG-MGF as an active ingredient or generic name.[5] FDA's page of bulk drug substances that may present significant safety risks, current as of April 22, 2026, lists PEG-MGF under "Bulk drug substances nominated but withdrawn," substances "previously in category 2 of the interim policies" whose nominations "were withdrawn by the nominators."[2]

The entry says compounded drugs containing PEG-MGF "may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization." It continues: "FDA has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration."[2]

The plain peptide sits elsewhere. FDA's list of 503A nominations, updated May 14, 2026, puts "Mechano growth factor (MGF)" in category 3, "Bulk Drug Substances Nominated Without Adequate Support." PEG-MGF itself is in none of the three categories.[3]

An advisory meeting is not a decision. FDA says "[a]dvisory committees make nonbinding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so."[4] A 503A discussion is about whether pharmacies may compound with a nominated substance, not a finding that a drug is safe or effective.[3] Separately, the World Anti-Doping Agency's 2026 Prohibited List names "Mechano growth factors (MGFs)" under S2.3, growth factors, prohibited at all times.[6]

The human evidence

The human studies measured the body's own MGF, not a dose of it

A ClinicalTrials.gov intervention search for mechano growth factor on October 10, 2026 returned 105 studies, mostly of IGF-1, growth hormone and drugs aimed at the IGF-1 receptor, but no study listing MGF or PEG-MGF as an intervention; searches for "MGF" and "PEG-MGF" found none either.[7] A PubMed search for "PEG-MGF" the same day returned a single record, a 2026 narrative review.[8]

Limiting PubMed's mechano growth factor records to clinical trials returns six papers.[9] None gave MGF. Each measured MGF messenger RNA in muscle samples after something else: resistance exercise in three, therapeutic ultrasound in one, electrical muscle stimulation after abdominal surgery in one, and growth hormone with resistance training in older men in one.[9]

A typical example: in 2003, a London group had eight young and seven older adults do heavy single-leg knee extensions and biopsied both legs 2.5 hours later. MGF messenger RNA rose significantly in the young subjects but not the older ones, and at rest it was about 100-fold lower than the other IGF-1 transcript measured, IGF-IEa.[11] That is evidence that the body makes this transcript in response to loading. It says nothing about injecting a synthetic or pegylated version.

The 2026 review that is PubMed's only PEG-MGF record makes the same point. It calls PEG-MGF a product "marketed as a PEGylated form" of MGF, says the literature cited for it is "largely based on IGF-1Ec/MGF biology and synthetic E-domain peptide constructs, rather than on PEG-MGF as a clinically characterised drug entity," and warns that because pegylation "fundamentally alters pharmacokinetics and tissue exposure," effects of the native peptide "cannot be assumed to apply."[19] It concludes that claims PEG-MGF "reliably accelerates recovery or improves body composition in humans remain unproven, and robust RCTs in human populations are lacking."[19]

The laboratory evidence

The founding cell result did not replicate

The idea dates to 1996, when Goldspink and colleagues reported an IGF-1 messenger RNA isoform expressed in response to mechanical stress.[17] The IGF-1 gene can be spliced in more than one way, and one variant, IGF-1Ec in humans, carries a distinctive end segment, the E-domain; a synthetic 24-residue peptide from that segment came to be called the MGF peptide.[17][12] In 2002 Yang and Goldspink reported that this E-domain peptide, which they called MGF, "inhibits terminal differentiation whilst increasing myoblast proliferation" in a cell model, and that its effect appeared to run through a receptor other than the IGF-1 receptor.[10]

A 2010 review led by a U.S. Army researcher drew a line that still matters. It noted that a synthetic peptide "corresponding to the 24 most C-terminal residues" had been shown to promote cell proliferation, but that "no analogous peptide product of the Igf1 gene has been identified in or isolated from cultured cells, their conditioned medium, or in vivo animal tissues or biological fluids."[12] A 2015 study later reported increased MGF protein in intestinal muscle cells from people with fibrostenotic Crohn's disease, so that question is not closed.[13]

The direct test came in 2014. Researchers at two pharmaceutical companies reported that MGF peptide at concentrations up to 500 ng/mL "failed to increase the proliferation" of mouse C2C12 cells or primary human skeletal muscle myoblasts, while every cell type responded to mature IGF-1 or full-length IGF-1Eb.[14] MGF also failed to inhibit differentiation, showed no significant effect on primary mouse muscle stem cells, and produced no activating response in cardiac muscle cells in native or stabilized form. The authors wrote that the results "call in to question whether there is a physiological role for MGF."[14]

A 2016 receptor study adds a twist. Human MGF peptide and a stabilized analog it called Goldspink-MGF produced no IGF-1 receptor activation. A longer "full-length MGF" protein did activate the receptor, with a maximal effect similar to IGF-1 at high concentrations (89-fold against 77-fold) but a half-maximal concentration about nine times higher (7.83 against 0.86 nmol/L).[15] In other words, the long protein acted on the IGF-1 receptor, less potently than IGF-1, which is a different claim from the short peptide's proposed separate mechanism. All of these are cell experiments.

The products

Three analyses, three different molecules

Doping laboratories have looked at what is sold under the name. Each found something different.

From the abstracts of the three papers.[16][17][18] None of the three abstracts describes a product labelled PEG-MGF.

The Ghent group found both black-market preparations it examined were "C-terminal amidated analogues of human MGF" and concluded that "illegal MGF preparations are commercially available."[16] Thevis and colleagues characterized a protein with a monoisotopic mass of 12,264.9 Da and "a sequence closely related to IGF-1Ec," modified by "the elimination of the terminal lysine and a R109H substitution," which it showed could be detected at 0.25 ng/mL with adapted doping tests.[17] The Salt Lake City laboratory identified "a variant of mechano-growth factor (MGF), MGF R23H" in confiscated vials.[18]

An amidated MGF analogue, a variant labelled R23H and a 12 kDa protein are different substances, and the receptor work above suggests the long and short forms may not even act the same way.[15] A PubMed search found no published analysis of a product sold as PEG-MGF,[8] and the name alone does not say which MGF was pegylated or how. That is consistent with FDA's own note on "complexities with regard to peptide-related impurities and API characterization."[2]

Three things this note is not saying

It is not saying IGF-1 splicing is fiction. The body does make the IGF-1Ec transcript, and it rises in young muscle after heavy loading.[11]

It is not saying MGF peptides have no biological effect anywhere. Animal and cell studies in muscle and heart are reviewed in the 2026 paper, which treats them as preclinical and heterogeneous.[19]

It is not predicting the advisory committee. No meeting date, briefing document or nominated use is public, and any recommendation would be nonbinding.[1][4] What it is saying is that the panel will be discussing a substance with no human data, an unsettled core mechanism, and no single agreed identity on the market.

Questions people are asking